TORONTO, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. ("Gemoscan" or the "Company") – (TSX-V:GES) (MUN:1GE) is pleased to announce the appointment of Ms. Elisa Swern to the Board of Directors and Dr. Daniel Bringleson, DC as Senior Vice President of Clinic Operations; both effective immediately. Dr. Bringleson will report to President and CEO, Brian Kalish.
Ms. Swern currently holds the position of Vice President Pricing and Promotions for Loblaw Companies Ltd ("LCL"). Her previous roles at LCL include: Executive level roles in Strategy and Supply Chain. Prior to joining LCL, Ms. Swern led the Supply Chain Retail Practice area for IBM Canada and was a management consultant with PriceWaterhouseCoopers. Ms. Swern specializes in building and implementing business transformation and competitive strategies.
Dr. Daniel Bringleson, DC is a doctor of chiropractic. Prior to joining the Company, he spent twelve years as a partner and clinic operator, building Physiomed Kennedy Inc., now a Gemoscan company. Dr. Bringleson is currently also a franchise co-owner at four other paramedical locations within the Greater Toronto Area. Dr. Bringleson received his doctorate from the Canadian Memorial Chiropractic College in 2001 after completing his Bachelor of Physical and Health Education degree at the University of Toronto in 1997 as Valedictorian. Dr. Bringleson remains a member in good standing with the College of Chiropractors of Ontario, the Canadian Chiropractic Association and the Ontario Chiropractic Association.
"We are excited to welcome Ms. Swern to our Board and Dr. Bringleson to our management team. These appointments are key considerations as we continue to build our business and seek to dominate the rapidly emerging retail healthcare sector. Ms. Swern's experience and position in the traditional Canadian retail landscape will undoubtedly help our business and our pioneering, retailed focused wellness programs; while Dr. Bringleson's clinical and operational proficiency will play an important role as we grow our market through acquiring and operating paramedical healthcare clinics." Said Brian Kalish, President and CEO.
About Gemoscan Canada, Inc.
Gemoscan is an industry leader in food intolerance management and maintains a first-to- market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODE™ Food Intolerance System and the MenuWise™ Food Intolerance Plan, personalized naturopathically supervised nutritional programs that promote well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available. Gemoscan also owns and operates Physiomed Kennedy Inc., a multidisciplinary paramedical clinic, located in Toronto, Ontario.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward - looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.